Log in

Vanda Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VNDA)

$13.59
-0.09 (-0.66 %)
(As of 10/20/2019 04:00 PM ET)
Today's Range
$13.42
Now: $13.59
$13.76
50-Day Range
$12.41
MA: $13.46
$14.18
52-Week Range
$11.83
Now: $13.59
$33.44
Volume422,499 shs
Average Volume577,598 shs
Market Capitalization$723.94 million
P/E Ratio28.31
Dividend YieldN/A
Beta0.32
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$193.12 million
Cash Flow$0.53 per share
Book Value$5.25 per share

Profitability

Net Income$25.20 million

Miscellaneous

Employees270
Market Cap$723.94 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.


Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its earnings results on Wednesday, July, 31st. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.24. The biopharmaceutical company had revenue of $59.06 million for the quarter, compared to the consensus estimate of $54.19 million. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the firm posted $0.15 earnings per share. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Vanda Pharmaceuticals.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $215-225 million, compared to the consensus revenue estimate of $219.56 million.

What price target have analysts set for VNDA?

8 brokerages have issued 1-year price objectives for Vanda Pharmaceuticals' stock. Their forecasts range from $17.00 to $52.00. On average, they expect Vanda Pharmaceuticals' share price to reach $28.67 in the next twelve months. This suggests a possible upside of 110.9% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

What is the consensus analysts' recommendation for Vanda Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals.

What are Wall Street analysts saying about Vanda Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (10/5/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating and $17 target price on VNDA shares as we continue to see limited upside from these levels given a relatively risky pipeline, for which we believe should only be assigned modest value, and a base business that seems more-or-less fully valued. Overall, the quarter looked good with top and bottom line beats driven by Hetlioz and meaningfully lower R&D spend. With that said, 2019 sales guidance for both Hetlioz and Fanapt remain unchanged, though management did update its cash guidance and expects to end 2019 with more cash than previously guided due to the lower spend throughout the year. As we highlighted in our recent deep dive (link here), we see few upside opportunities and more downside risks over the next 12 months and believe the overhang from the FDA lawsuit/tradipitant chronic safety will likely keep shares relatively range bound, in our view." (7/31/2019)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

Media coverage about VNDA stock has been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a news impact score of 0.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Vanda Pharmaceuticals.

Who are some of Vanda Pharmaceuticals' key competitors?

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include Zogenix (ZGNX), FibroGen (FGEN), Array Biopharma (ARRY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), GW Pharmaceuticals PLC- (GWPH), Sarepta Therapeutics (SRPT) and Micron Technology (MU).

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%), Pacer Advisors Inc. (0.03%), Clarus Wealth Advisors (0.02%), Meeder Asset Management Inc. (0.01%) and North Star Investment Management Corp. (0.01%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Which major investors are buying Vanda Pharmaceuticals stock?

VNDA stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Clarus Wealth Advisors, Pacer Advisors Inc., North Star Investment Management Corp. and Meeder Asset Management Inc.. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $13.59.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $723.94 million and generates $193.12 million in revenue each year. The biopharmaceutical company earns $25.20 million in net income (profit) each year or $0.48 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.View Additional Information About Vanda Pharmaceuticals.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is http://www.vandapharmaceuticals.com/.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  459 (Vote Outperform)
Underperform Votes:  334 (Vote Underperform)
Total Votes:  793
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Featured Article: Buyback

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel